Patheon Inc. Reports Fourth Quarter and Full Fiscal 2012 Results
TORONTO, Dec. 17, 2012 /PRNewswire/ - Patheon Inc. (PTI.TO), a leading provider of contract development and manufacturing services to the global pharmaceutical industry, announced today full year and fourth quarter results for fiscal 2012.
For the full year:
•Revenues were $749.1 million versus $700.0 million last year, an increase of 7.0 percent. Excluding the $50.3 million benefit from the contract cancellation recorded last year, revenue would have increased by 15.3 percent. •Gross profit for the year was $159.3 million compared to $131.8 million last year, an increase of 20.9 percent. Excluding the $50.3 million benefit from the contract cancellation recorded last year, gross profit would have increased by 95.5 percent.
For the full year:
•Revenues were $749.1 million versus $700.0 million last year, an increase of 7.0 percent. Excluding the $50.3 million benefit from the contract cancellation recorded last year, revenue would have increased by 15.3 percent. •Gross profit for the year was $159.3 million compared to $131.8 million last year, an increase of 20.9 percent. Excluding the $50.3 million benefit from the contract cancellation recorded last year, gross profit would have increased by 95.5 percent.